Cargando…
Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors
PURPOSE: IL2 immunotherapy has the potential to elicit immune-mediated tumor lysis via activation of effector immune cells, but clinical utility is limited due to pharmacokinetic challenges as well as vascular leak syndrome and other life-threatening toxicities experienced by patients. We developed...
Autores principales: | Nash, Amanda M., Aghlara-Fotovat, Samira, Castillio, Bertha, Hernandez, Andrea, Pugazenthi, Aarthi, Lee, Hyun-Sung, Jang, Hee-Jin, Nguyen, Annie, Lu, Alexander, Burt, Bryan M., Ghanta, Ravi K., Veiseh, Omid |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9713361/ https://www.ncbi.nlm.nih.gov/pubmed/35993913 http://dx.doi.org/10.1158/1078-0432.CCR-22-1493 |
Ejemplares similares
-
Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study
por: Nathenson, Michael J., et al.
Publicado: (2022) -
Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors
por: Nash, Amanda M., et al.
Publicado: (2022) -
The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma
por: Cheng, Zhao, et al.
Publicado: (2022) -
Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer
por: Xia, Youli, et al.
Publicado: (2022) -
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
por: Bergamino, Milana A., et al.
Publicado: (2022)